Targeting monocytes/macrophages in the treatment of rheumatoid arthritis

Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches w...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2013-04, Vol.52 (4), p.590-598
Main Authors: Davignon, Jean-Luc, Hayder, Myriam, Baron, Michel, Boyer, Jean-Frédéric, Constantin, Arnaud, Apparailly, Florence, Poupot, Rémy, Cantagrel, Alain
Format: Article
Language:English
Subjects:
Animals
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - therapy
Dendrimers
Gene Silencing - drug effects
Group IV Phospholipases A2 - genetics
Humans
Macrophages - enzymology
Molecular Targeted Therapy - methods
Monocytes - enzymology
RNA, Small Interfering - therapeutic use
Tumor Necrosis Factor-alpha - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF-α antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kes304